Core A: Administration and Bioanalysis Core

核心 A:管理和生物分析核心

基本信息

  • 批准号:
    8904707
  • 负责人:
  • 金额:
    $ 17.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-19 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

The Administrative Core will provide (1) professional and (2) administrative functions to the Program ' Project. 1) Professional Component The professional component is designed to monitor the overall progress ofthe TCORS P50, solve problems as they arise, effect quality control, and provide direction for future research. Drs. Tarran and Doerschuk will provide this support to the Core. They will chair weekly meetings with Project and Core Leaders to ensure smooth, coordinated functioning of the projects and to develop new research directions. This function will be coordinated with meetings of the Advisory Committee. The Advisory Committee has been named and consists of: 1) David Peden, MD, Professor of Pediatrics, Medicine & Microbiology/ Immunology, Director ofthe UNC School of Medicine's Center for Environmental Medicine, Asthma and Lung Biology; 2) James Swenberg, PhD, Kenan Distinguished Professor of Environmental Sciences & Engineering; former Director ofthe Curriculum in Toxicology and 3) Richard Boucher, MD, Executive Associate Dean for Translational Research, Distinguished Professor of Medicine, Director of the Cystic Fibrosis/Pulmonary Research and Treatment Center and an expert on obstructive lung diseases. In addition, Drs. Tarran and Doerschuk will chair a monthly administrative luncheon that is designed to monitor P50 personnel and budgetary matters and will monitor the Cores to ensure adequate support for the Projects. This Core will also be the interface with administrators of different departments and divisions within UNC as well as the University Office of Contracts and Grants. 2) Administrative Component a. Budgetary and Programmatic Support: The administrative component will provide the support services required to assure the smooth functioning of each program element. These services will include the management of budget and personnel, and overseeing of communications, publication, and IT facilities. The goal of this facet of the Core will be to provide efficient administrative "resources to all P50~prdject and core investigators so that individual investigators' time for administrative matters will be minimized, permitting maximum time for research endeavors. b. Human Subjects The PSO obtains induced sputum, bronchoalveolar lavage and lower airways epithelial cells (Projects II and 2) and excised human lungs so that the Cell Culture Core (Core C) can provide P50 investigators with well-differentiated cell culture models. In addition, mouse models of smoke exposure will also be tested (Projects II and III). The Administrative Core will facilitate Human Rights Protocol and lACUC submission and compliance with all Federal/University guidelines for human research. c. Personnel Dr. Tarran will be the P50 Principal Investigator and the Core Leader. He will be responsible for all scientific and administrative aspects ofthe P50. He has had administrative experience in leadership of NIH multidisciplinary research programs, including his serving as a Project Leader and Co-lnvestigator on a SCCOR on Airway Biology/Pathogenesis of Cystic Fibrosis and COPD (HL0849334) from 2006-2012 and a PPG from 2007-present (HL110873)
行政核心将为计划项目提供(1)专业和(2)行政职能。 1)专业组件专业组件的目的是监控TCORS P50的整体进展,解决出现的问题,进行质量控制,并为未来的研究提供方向。塔伦博士和多尔舒克博士将为核心提供这种支持。他们将主持每周与项目和核心领导人的会议,以确保项目的顺利,协调运作,并制定新的研究方向。这一职能将与咨询委员会的会议协调。咨询委员会的名称已经确定,其组成如下: 1)大卫佩登,医学博士,儿科学,医学和微生物学/免疫学教授,医学院环境医学,哮喘和肺生物学中心主任; 2)James Swenberg,博士,环境科学与工程凯南杰出教授;毒理学课程前主任, 3)Richard Boucher,医学博士,转化研究执行副院长,医学杰出教授,囊性纤维化/肺研究和治疗中心主任,阻塞性肺疾病专家。 此外,Tarran和Doerschuk博士将主持每月一次的行政午餐会,旨在监测P50的人事和预算事项,并将监测核心,以确保对项目的充分支持。这一核心也将是与不同部门和部门的管理人员以及合同和赠款大学办公室的接口。 2)行政部分 a.预算和方案支助: 行政部门将提供必要的支助服务,以确保工作顺利进行。 每个程序元素的功能。这些服务将包括预算和人事管理,以及监督通信、出版和信息技术设施。核心的这一方面的目标是为所有P50项目和核心研究者提供有效的行政资源,以便最大限度地减少单个研究者处理行政事务的时间,从而为研究工作提供最大的时间。 B.人类受试者 PSO获得诱导痰、支气管肺泡灌洗和下气道上皮细胞(项目II和2)以及切除的人肺,因此细胞培养核心(核心C)可以为P50研究者提供分化良好的细胞培养模型。此外,还将对接触烟雾的小鼠模型进行测试(项目II和III)。行政核心将促进人权协议和lACUC的提交,并遵守所有联邦/大学的人类研究指南。 C. Tarran博士将担任P50的主要研究者和核心负责人。他将负责P50的所有科学和行政方面。他在领导NIH多学科研究项目方面具有行政管理经验,包括2006-2012年担任关于气道生物学/囊性纤维化和COPD发病机制的SCCOR(HL 0849334)的项目负责人和联合研究员,以及2007年至今担任PPG(HL 110873)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT TARRAN其他文献

ROBERT TARRAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT TARRAN', 18)}}的其他基金

Novel Peptide Fusion Inhibitors for the Treatment of COVID-19
用于治疗 COVID-19 的新型肽融合抑制剂
  • 批准号:
    10379832
  • 财政年份:
    2022
  • 资助金额:
    $ 17.69万
  • 项目类别:
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
ELD607 Orai1 拮抗剂可增加肺部细菌清除率
  • 批准号:
    10453601
  • 财政年份:
    2020
  • 资助金额:
    $ 17.69万
  • 项目类别:
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
ELD607 Orai1 拮抗剂可增加肺部细菌清除率
  • 批准号:
    10404327
  • 财政年份:
    2020
  • 资助金额:
    $ 17.69万
  • 项目类别:
Do E-Cigarette Users Airways Have an Altered Lipid Content?
电子烟使用者的呼吸道脂质含量是否发生改变?
  • 批准号:
    10037769
  • 财政年份:
    2020
  • 资助金额:
    $ 17.69万
  • 项目类别:
Do E-Cigarette Users Airways Have an Altered Lipid Content?
电子烟使用者的呼吸道脂质含量是否发生改变?
  • 批准号:
    10220134
  • 财政年份:
    2020
  • 资助金额:
    $ 17.69万
  • 项目类别:
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
ELD607 Orai1 拮抗剂可增加肺部细菌清除率
  • 批准号:
    10080273
  • 财政年份:
    2020
  • 资助金额:
    $ 17.69万
  • 项目类别:
Project 1: The Effects of New and Emerging Tobacco Products on Lung Hyd
项目 1:新型和新兴烟草产品对肺水肿的影响
  • 批准号:
    8904703
  • 财政年份:
    2013
  • 资助金额:
    $ 17.69万
  • 项目类别:
The Impact of Tobacco Exposure on the Lungs Innate Defense System
烟草暴露对肺部先天防御系统的影响
  • 批准号:
    9328114
  • 财政年份:
    2013
  • 资助金额:
    $ 17.69万
  • 项目类别:
The Impact of Tobacco Exposure on the Lungs Innate Defense System
烟草暴露对肺部先天防御系统的影响
  • 批准号:
    8582362
  • 财政年份:
    2013
  • 资助金额:
    $ 17.69万
  • 项目类别:
The Impact of Tobacco Exposure on the Lungs Innate Defense System
烟草暴露对肺部先天防御系统的影响
  • 批准号:
    8737945
  • 财政年份:
    2013
  • 资助金额:
    $ 17.69万
  • 项目类别:

相似海外基金

Advisory Committees
咨询委员会
  • 批准号:
    7353899
  • 财政年份:
    2006
  • 资助金额:
    $ 17.69万
  • 项目类别:
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
  • 批准号:
    0451289
  • 财政年份:
    2005
  • 资助金额:
    $ 17.69万
  • 项目类别:
    Standard Grant
Advisory Committees
咨询委员会
  • 批准号:
    7557224
  • 财政年份:
  • 资助金额:
    $ 17.69万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    7902286
  • 财政年份:
  • 资助金额:
    $ 17.69万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    7691385
  • 财政年份:
  • 资助金额:
    $ 17.69万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    8150373
  • 财政年份:
  • 资助金额:
    $ 17.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了